Patents by Inventor Mark D. Sternlicht

Mark D. Sternlicht has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Connective tissue growth factor antisense oligonucleotides
    Patent number: 9115356
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Grant
    Filed: March 7, 2014
    Date of Patent: August 25, 2015
    Assignee: FIBROGEN, INC.
    Inventors: Todd W. Seeley, Mark D. Sternlicht
  • Connective tissue growth factor antisense oligonucleotides
    Patent number: 8802839
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Grant
    Filed: July 11, 2012
    Date of Patent: August 12, 2014
    Assignee: FibroGen, Inc.
    Inventors: Mark D. Sternlicht, Todd W. Seeley
  • Connective Tissue Growth Factor Antisense Oligonucleotides
    Publication number: 20140187610
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Application
    Filed: March 7, 2014
    Publication date: July 3, 2014
    Applicant: FibroGen, Inc.
    Inventors: Todd W. Seeley, Mark D. Sternlicht
  • CONNECTIVE TISSUE GROWTH FACTOR ANTISENSE OLIGONUCLEOTIDES
    Publication number: 20130178510
    Abstract: The present invention relates to antisense oligonucleotides that target human CTGF mRNA and inhibit CTGF mRNA expression. Additionally, regions of human CTGF mRNA that are exceptionally sensitive to antisense inhibition are disclosed. Pharmaceutical compositions comprising the antisense oligonucleotides are further disclosed. These compositions are useful for treating disorders and conditions that are associated with or influenced by CTGF expression.
    Type: Application
    Filed: July 11, 2012
    Publication date: July 11, 2013
    Applicant: FibroGen, Inc.
    Inventors: Mark D. Sternlicht, Todd W. Seeley